☆ 4.3 Meeting Abstract

Cardiovascular adverse drug reactions of Ibrutinib, Idelalisib, Acalabrutinib, and Venetoclax used in chronic lymphocytic leukemia: Systematic review -meta--analysis and Signal detection by disproportionality analysis from VigiBase®

FUNDAMENTAL & CLINICAL PHARMACOLOGY (2021)

Add to Collection

Journal

FUNDAMENTAL & CLINICAL PHARMACOLOGY
Volume 35, Issue -, Pages 38-39

Publisher

WILEY

Keywords

chronic lymphocytic leukemia; safety profile; cardiovascular adverse drug reaction; meta-analysis; pharmacovigilance; VigiBase (R)

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.